Immune Checkpoint Inhibitor-Related Bullous Pemphigoid with Negative Direct Immunofluorescence during Pembrolizumab Plus Lenvatinib Therapy: A Case Report

Introduction

Bullous pemphigoid (BP) is a rare but clinically significant cutaneous immune-related adverse event (irAE) of immune checkpoint inhibitor (ICI) therapy. It is most often described during treatment of melanoma, lung cancer, and renal cell carcinoma, whereas reports in gynecologic oncology, and specifically during lenvatinib plus pembrolizumab (LP) therapy, remain scarce.